Related references
Note: Only part of the references are listed.Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial
Kristin B Highland et al.
Lancet Respiratory Medicine (2021)
Recurrence of progressive skin involvement following discontinuation or dose reduction of Mycophenolate Mofetil treatment in patients with diffuse Systemic Sclerosis
Fabian A. Mendoza et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial
Dinesh Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Systemic sclerosis: Advances towards stratified medicine
A. Quinlivan et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2020)
Bispecific Antibodies for Autoimmune and Inflammatory Diseases: Clinical Progress to Date
Qi Zhao
BIODRUGS (2020)
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
Arezoo Hosseini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2020)
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
Dinesh Khanna et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis
Robert Spiera et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Lorinda Chung et al.
LANCET RHEUMATOLOGY (2020)
The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib
Wenxia Wang et al.
JOURNAL OF SCLERODERMA AND RELATED DISORDERS (2020)
EFFICACY AND SAFETY OF ROMILKIMAB IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC): RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 24-WEEK, PROOF OF CONCEPT STUDY
Y. Allanore et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Emerging targets of disease-modifying therapy for systemic sclerosis
Elizabeth R. Volkmann et al.
NATURE REVIEWS RHEUMATOLOGY (2019)
Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study
Muriel Elhai et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
Oliver Distler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The immunopathogenesis of fibrosis in systemic sclerosis
M. Brown et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Contemporary epidemiology of systemic sclerosis: A population-based cohort study in the United Kingdom
Luis A. Garcia Rodriguez et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Challenges in systemic sclerosis trial design
Christopher P. Denton
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)
Robert Spiera et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
Vivien M. Hsu et al.
JOURNAL OF RHEUMATOLOGY (2018)
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial
Jessica K. Gordon et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease
Hua Xiao et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2018)
New-generation JAK inhibitors: how selective can they be?
Guro L. Goll et al.
LANCET (2018)
Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial
Geetabali Sircar et al.
RHEUMATOLOGY (2018)
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study
Yannick Allanore et al.
ARTHRITIS & RHEUMATOLOGY (2018)
T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
Goncalo Boleto et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
John Gerry Coghlan et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Update of EULAR recommendations for the treatment of systemic sclerosis
Otylia Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82
Robert Lafyatis et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial
Peter Saunders et al.
TRIALS (2017)
Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Jingang Huang et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis
Nadira Ruzehaji et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Cannabinoids, inflammation, and fibrosis
Robert B. Zurier et al.
FASEB JOURNAL (2016)
Wnt/β-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration
Dikshya Bastakoty et al.
FASEB JOURNAL (2016)
An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial
Dinesh Khanna et al.
JOURNAL OF RHEUMATOLOGY (2016)
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna et al.
LANCET (2016)
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Lutz Wollin et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Systemic sclerosis
Yannick Allanore et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Luca Richeldi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis
Lucille Desallais et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Lysophosphatidic acid (LPA) and its receptors: Role in airway inflammation and remodeling
Yutong Zhao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis
Angelo De Lauretis et al.
JOURNAL OF RHEUMATOLOGY (2013)
Riociguat for the Treatment of Pulmonary Arterial Hypertension
Hossein-Ardeschir Ghofrani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interleukin-6: a new therapeutic target in systemic sclerosis?
Steven O'Reilly et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2013)
Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis
Estrella Garcia Gonzalez et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Pomalidomide is effective for prevention and treatment of experimental skin fibrosis
Simon Weingaertner et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis
Korsa Khan et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Belimumab: Review of Use in Systemic Lupus Erythematosus
Eric G. Boyce et al.
CLINICAL THERAPEUTICS (2012)
Antiinflammatory and Antifibrotic Effects of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in a Murine Model of Interstitial Lung Disease
Galina S. Bogatkevich et al.
ARTHRITIS AND RHEUMATISM (2011)
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo
Elizabeth Ward et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Role of IL-13 in systemic sclerosis
Patrizia Fuschiotti
CYTOKINE (2011)
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Paul W. Noble et al.
LANCET (2011)
Coagulation and Autoimmunity in Scleroderma Interstitial Lung Disease
Anna Ludwicka-Bradley et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2011)
RILONACEPT IN THE TREATMENT OF CHRONIC INFLAMMATORY DISORDERS
Michael F. McDermott
DRUGS OF TODAY (2009)
TGF-β and Smad3 signaling link inflammation to chronic fibrogenesis
P Bonniaud et al.
JOURNAL OF IMMUNOLOGY (2005)
Altered blood B lymphocyte Homeostasis in systemic sclerosis - Expanded naive B cells and diminished but activated memory B cells
S Sato et al.
ARTHRITIS AND RHEUMATISM (2004)
Quantitative genetic variation in CD19 expression correlates with autoimmunity
S Sato et al.
JOURNAL OF IMMUNOLOGY (2000)
Immune stimulation in scleroderma patients treated with thalidomide
SJ Oliver et al.
CLINICAL IMMUNOLOGY (2000)
The p300/CBP acetyltransferases function as transcriptional coactivators of β-catenin in vertebrates
A Hecht et al.
EMBO JOURNAL (2000)
Share Paper
